Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

1.

Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience.

Lin CP, Lin WY, Lin FS, Lee YS, Jeng CS, Sun WZ.

J Formos Med Assoc. 2012 May;111(5):253-7. doi: 10.1016/j.jfma.2011.03.005. Epub 2012 Mar 11.

PMID:
22656395
[PubMed - indexed for MEDLINE]
2.

An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).

Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Català E, Bryce DA, Cousins M, Pool GE.

Ann Oncol. 2005 May;16(5):825-33. Epub 2005 Apr 7.

PMID:
15817596
[PubMed - indexed for MEDLINE]
Free Article
3.
4.

Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy.

Kumar K, Kelly M, Pirlot T.

Surg Neurol. 2001 Feb;55(2):79-86; discussion 86-8.

PMID:
11301086
[PubMed - indexed for MEDLINE]
5.

Long-term intrathecal drug administration for chronic nonmalignant pain.

Duarte RV, Raphael JH, Sparkes E, Southall JL, LeMarchand K, Ashford RL.

J Neurosurg Anesthesiol. 2012 Jan;24(1):63-70. doi: 10.1097/ANA.0b013e31822ff779.

PMID:
21904220
[PubMed - indexed for MEDLINE]
6.

Pain management, including intrathecal pumps.

Smith TJ, Swainey C, Coyne PJ.

Curr Oncol Rep. 2004 Jul;6(4):291-6. Review.

PMID:
15161583
[PubMed - indexed for MEDLINE]
7.

Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.

Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Català E, Bryce DA, Coyne PJ, Pool GE; Implantable Drug Delivery Systems Study Group.

J Clin Oncol. 2002 Oct 1;20(19):4040-9.

PMID:
12351602
[PubMed - indexed for MEDLINE]
8.

Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.

Ripamonti C, Brunelli C.

J Clin Oncol. 2003 Jul 15;21(14):2801-2; author reply 2802-3. No abstract available.

PMID:
12860959
[PubMed - indexed for MEDLINE]
9.

Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain.

Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K.

J Pain. 2003 Oct;4(8):441-7.

PMID:
14622664
[PubMed - indexed for MEDLINE]
10.

Intrathecal therapy for cancer and non-cancer pain.

Hayek SM, Deer TR, Pope JE, Panchal SJ, Patel VB.

Pain Physician. 2011 May-Jun;14(3):219-48. Review.

PMID:
21587327
[PubMed - indexed for MEDLINE]
Free Article
11.

Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer.

Gestin Y, Vainio A, Pégurier AM.

Acta Anaesthesiol Scand. 1997 Jan;41(1 Pt 1):12-7.

PMID:
9061109
[PubMed - indexed for MEDLINE]
12.

A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain.

Anderson VC, Burchiel KJ.

Neurosurgery. 1999 Feb;44(2):289-300; discussion 300-1.

PMID:
9932882
[PubMed - indexed for MEDLINE]
13.

Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer.

Gilmer-Hill HS, Boggan JE, Smith KA, Frey CF, Wagner FC Jr, Hein LJ.

Surg Neurol. 1999 Jan;51(1):6-11.

PMID:
9952116
[PubMed - indexed for MEDLINE]
14.

Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices.

Stearns L, Boortz-Marx R, Du Pen S, Friehs G, Gordon M, Halyard M, Herbst L, Kiser J.

J Support Oncol. 2005 Nov-Dec;3(6):399-408.

PMID:
16350425
[PubMed - indexed for MEDLINE]
15.

Intrathecal morphine pump for neuropathic cancer pain: a case report.

Gogia V, Chaudhary P, Ahmed A, Khurana D, Mishra S, Bhatnagar S.

Am J Hosp Palliat Care. 2012 Aug;29(5):409-11. doi: 10.1177/1049909111419650. Epub 2011 Aug 25.

PMID:
21868426
[PubMed - indexed for MEDLINE]
16.

Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates.

Upadhyay SP, Mallick PN.

Am J Hosp Palliat Care. 2012 Aug;29(5):388-98. doi: 10.1177/1049909111426134. Epub 2011 Nov 15. Review.

PMID:
22089523
[PubMed - indexed for MEDLINE]
17.

Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance?

Sallerin-Caute B, Lazorthes Y, Deguine O, Francés B, Verdié JC, Charlet JP, Bastide R.

Neurosurgery. 1998 Jan;42(1):44-9; discussion 49-50.

PMID:
9442502
[PubMed - indexed for MEDLINE]
18.

Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.

Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S.

Clin J Pain. 2007 Nov-Dec;23(9):793-8.

PMID:
18075407
[PubMed - indexed for MEDLINE]
19.

Continuous intrathecal morphine infusion in patients with vertebral fractures due to osteoporosis.

Shaladi A, Saltari MR, Piva B, Crestani F, Tartari S, Pinato P, Micheletto G, Dall'Ara R.

Clin J Pain. 2007 Jul-Aug;23(6):511-7.

PMID:
17575491
[PubMed - indexed for MEDLINE]
20.

Randomized clinical trial of an implantable drug delivery system.

Davis MP, Walsh D, Lagman R, LeGrand SB.

J Clin Oncol. 2003 Jul 15;21(14):2800-1; author reply 2802-3. No abstract available.

PMID:
12860958
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk